Navigation Links
DaVita Board of Directors Increases Share Repurchase Authorization
Date:5/7/2008

EL SEGUNDO, Calif., May 7 /PRNewswire-FirstCall/ -- DaVita Inc. (NYSE: DVA) announced that its Board of Directors has authorized an increase to its current stock repurchase program. The increase, together with previously available amounts, authorizes the repurchase of $250,000,000 of the Company's common stock. The stock repurchase program has no expiration date.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

Rich Whitney, CFO, commented, "We have historically maintained a board authorization in this range which allows us flexibility to return capital to our shareholders over time."

Purchases may be made in the open market or in privately negotiated transactions from time to time at management's discretion depending on market conditions and other considerations. The repurchase program may be suspended or discontinued at any time. Shares of stock repurchased under the plan will be held as treasury shares.

As of May 1, 2008, DaVita had approximately 104,700,000 shares of common stock outstanding.

DaVita Inc. is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages over 1,300 outpatient facilities and acute units in over 700 hospitals located in 43 states and the District of Columbia, serving approximately 107,000 patients.


'/>"/>
SOURCE DaVita Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. DaVita Receives Civil Complaint
2. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
3. DaVita Teammates Bicycling 230 Miles for Kidney Disease Education
4. DaVita Volunteers Raise More than $1,000,000 for Nationwide Kidney Education and Prevention Programs
5. DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires
6. DaVita to Open First Independent Dialysis Clinic in Fargo-Moorhead
7. DaVita Nurse Gives Keynote Speech to St. Georges Hospital Vascular Access Annual Meeting in London
8. DaVita Inc. to Present at JPMorgan Healthcare Conference
9. DaVita and Phoenix-Based Southwest Kidney Institute Form Broad Partnership
10. Nations Leading Dialysis Provider - DaVita - Partners with eDiets(R) to Launch One-of-a-Kind Diet Helper Online Nutrition and Meal Planning Tool for Late-Stage Kidney Disease Patients and Caregivers
11. DaVita Announces Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... An April 24th article on Yahoo! ... 180 pounds with the help of a weight loss surgery. The woman, declaring “I will ... that have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider ... Online(TM), which enables sleep physicians to create and edit their interpretation reports. This ... provides a familiar interface that does not require additional training to use. It ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic ... has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board ... Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... ... cardiac or hERG liability could substantially improve drug safety and minimize the cost ... provided for validating ion channel inhibition using cell lines and for cardiac toxicity ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: